Oncotelic Therapeutics, Inc (OTLC)
0.05
0.00 (0.00%)
Upcoming Events
Latest Headlines
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
May 15, 2026 9:00 AM - Globe NewsWire
NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations
May 15, 2026 8:30 AM - Globe NewsWire
Form 10-Q Oncotelic Therapeutics, For: Mar 31
May 14, 2026 5:16 PM - SEC Filing
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
May 14, 2026 8:30 AM - Globe NewsWire
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
May 13, 2026 8:30 AM - Globe NewsWire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
May 12, 2026 8:30 AM - Globe NewsWire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026 8:30 AM - Globe NewsWire
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease
May 6, 2026 8:30 AM - Globe NewsWire
Form 8-K Oncotelic Therapeutics, For: May 01
May 5, 2026 4:22 PM - SEC Filing
NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways
April 24, 2026 8:30 AM - Globe NewsWire
Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy
April 24, 2026 8:00 AM - Globe NewsWire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
April 23, 2026 8:31 AM - Globe NewsWire
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
April 22, 2026 8:30 AM - Globe NewsWire
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026 8:30 AM - Globe NewsWire
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
April 16, 2026 11:43 AM - Globe NewsWire
Form 8-K Oncotelic Therapeutics, For: Apr 16
April 16, 2026 9:01 AM - SEC Filing
Form 10-K Oncotelic Therapeutics, For: Dec 31
April 15, 2026 4:32 PM - SEC Filing
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
April 10, 2026 8:30 AM - Globe NewsWire
AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards
April 7, 2026 12:49 PM - Globe NewsWire
Form 8-K Oncotelic Therapeutics, For: Mar 31
April 2, 2026 9:15 AM - SEC Filing
Oncotelic partners with TechForce to commercialize AI robotics platform
April 2, 2026 8:30 AM - StreetInsider
Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
April 2, 2026 8:30 AM - Globe NewsWire
Form NT 10-K Oncotelic Therapeutics, For: Dec 31
March 31, 2026 5:15 PM - SEC Filing
Form 8-K Oncotelic Therapeutics, For: Mar 24
March 30, 2026 9:16 AM - SEC Filing
Form 8-K Oncotelic Therapeutics, For: Mar 23
March 30, 2026 6:07 AM - SEC Filing
Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
March 24, 2026 9:50 AM - Globe NewsWire
Full Article List
